Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9298MR)

This product GTTS-WQ9298MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9298MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3992MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ8384MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ14404MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ985MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ12096MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ647MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ12469MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ2624MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW